Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 14 | 2025 | 247 | 2.730 |
Why?
|
| Thoracic Surgery | 5 | 2022 | 13 | 2.020 |
Why?
|
| Pneumonectomy | 8 | 2022 | 34 | 1.890 |
Why?
|
| Databases, Factual | 6 | 2019 | 156 | 1.280 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2019 | 4 | 1.120 |
Why?
|
| Humans | 35 | 2025 | 12240 | 0.860 |
Why?
|
| Thoracic Wall | 2 | 2014 | 5 | 0.830 |
Why?
|
| Adenocarcinoma | 5 | 2017 | 61 | 0.770 |
Why?
|
| Esophageal Neoplasms | 2 | 2015 | 22 | 0.750 |
Why?
|
| Biology | 1 | 2022 | 6 | 0.740 |
Why?
|
| Phosphoproteins | 1 | 2022 | 13 | 0.740 |
Why?
|
| Postoperative Complications | 2 | 2022 | 385 | 0.620 |
Why?
|
| Gases | 1 | 2019 | 5 | 0.600 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2010 | 7 | 0.600 |
Why?
|
| Enteral Nutrition | 2 | 2010 | 29 | 0.590 |
Why?
|
| Clostridium Infections | 2 | 2009 | 19 | 0.580 |
Why?
|
| Heart Diseases | 2 | 2016 | 31 | 0.570 |
Why?
|
| Quality Improvement | 1 | 2019 | 78 | 0.550 |
Why?
|
| Male | 22 | 2025 | 6815 | 0.550 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2025 | 106 | 0.530 |
Why?
|
| Internationality | 1 | 2017 | 7 | 0.520 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 18 | 0.520 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 17 | 0.490 |
Why?
|
| Cardiology | 1 | 2016 | 26 | 0.490 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2021 | 7 | 0.480 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 71 | 0.470 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 4 | 0.460 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 4 | 0.460 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 12 | 0.460 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 23 | 0.450 |
Why?
|
| Female | 18 | 2025 | 6974 | 0.450 |
Why?
|
| Aged | 15 | 2019 | 4000 | 0.450 |
Why?
|
| Mucormycosis | 1 | 2015 | 2 | 0.440 |
Why?
|
| Lung Diseases, Fungal | 1 | 2015 | 5 | 0.440 |
Why?
|
| Biomarkers, Tumor | 6 | 2025 | 101 | 0.440 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 9 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 105 | 0.440 |
Why?
|
| Societies, Medical | 3 | 2019 | 48 | 0.420 |
Why?
|
| Surgical Mesh | 1 | 2014 | 15 | 0.410 |
Why?
|
| Herniorrhaphy | 1 | 2014 | 16 | 0.410 |
Why?
|
| Manubrium | 1 | 2014 | 1 | 0.410 |
Why?
|
| Replantation | 1 | 2014 | 4 | 0.410 |
Why?
|
| Clavicle | 1 | 2014 | 5 | 0.410 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 92 | 0.390 |
Why?
|
| Tricuspid Valve Prolapse | 1 | 2012 | 1 | 0.380 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2012 | 1 | 0.380 |
Why?
|
| Robotics | 1 | 2012 | 4 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2012 | 6 | 0.380 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 22 | 0.370 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 2152 | 0.370 |
Why?
|
| Adult | 10 | 2017 | 3557 | 0.360 |
Why?
|
| Retrospective Studies | 8 | 2022 | 1467 | 0.340 |
Why?
|
| Middle Aged | 13 | 2022 | 4043 | 0.330 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 28 | 0.320 |
Why?
|
| Risk Factors | 3 | 2022 | 1049 | 0.320 |
Why?
|
| Energy Intake | 1 | 2010 | 46 | 0.310 |
Why?
|
| Thoracotomy | 1 | 2009 | 9 | 0.300 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 45 | 0.300 |
Why?
|
| Critical Care | 1 | 2010 | 49 | 0.300 |
Why?
|
| Aneurysm, Infected | 1 | 2009 | 1 | 0.300 |
Why?
|
| Aortitis | 1 | 2009 | 1 | 0.300 |
Why?
|
| Clostridium septicum | 1 | 2009 | 1 | 0.300 |
Why?
|
| Aortic Aneurysm | 1 | 2009 | 6 | 0.290 |
Why?
|
| Inhibin-beta Subunits | 1 | 2009 | 1 | 0.290 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 29 | 0.290 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 8 | 0.290 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 43 | 0.290 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 128 | 0.280 |
Why?
|
| Hospital Costs | 1 | 2008 | 29 | 0.280 |
Why?
|
| Treatment Outcome | 8 | 2021 | 1478 | 0.270 |
Why?
|
| Intensive Care Units | 1 | 2008 | 119 | 0.260 |
Why?
|
| Prognosis | 4 | 2022 | 363 | 0.240 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 59 | 0.240 |
Why?
|
| Machine Learning | 1 | 2025 | 31 | 0.220 |
Why?
|
| Surgical Flaps | 2 | 2015 | 23 | 0.210 |
Why?
|
| Risk Assessment | 2 | 2019 | 295 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 23 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 70 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 168 | 0.200 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 5 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 9 | 0.180 |
Why?
|
| Lung | 1 | 2022 | 76 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2022 | 77 | 0.180 |
Why?
|
| Simulation Training | 1 | 2021 | 15 | 0.170 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2021 | 7 | 0.170 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 10 | 0.170 |
Why?
|
| Mass Screening | 2 | 2022 | 86 | 0.170 |
Why?
|
| Heart Failure | 1 | 2021 | 77 | 0.160 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2010 | 6 | 0.150 |
Why?
|
| Carcinoma | 2 | 2017 | 34 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 252 | 0.150 |
Why?
|
| Adolescent | 1 | 2022 | 989 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 6 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2022 | 36 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2019 | 23 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 16 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2018 | 6 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 4 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 10 | 0.140 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2018 | 9 | 0.140 |
Why?
|
| Surgeons | 1 | 2018 | 43 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2018 | 96 | 0.130 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 5 | 0.130 |
Why?
|
| Time Factors | 1 | 2019 | 695 | 0.130 |
Why?
|
| Lymphoma | 1 | 2017 | 16 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 726 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 97 | 0.130 |
Why?
|
| Melanoma | 1 | 2017 | 34 | 0.130 |
Why?
|
| History, 19th Century | 1 | 2016 | 6 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 13 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 18 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 13 | 0.120 |
Why?
|
| Sarcoma | 1 | 2017 | 59 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 37 | 0.120 |
Why?
|
| Ifosfamide | 1 | 2015 | 4 | 0.120 |
Why?
|
| Etoposide | 1 | 2015 | 15 | 0.120 |
Why?
|
| Cisplatin | 1 | 2015 | 25 | 0.110 |
Why?
|
| Thoracoscopy | 2 | 2019 | 12 | 0.110 |
Why?
|
| Bronchi | 1 | 2015 | 2 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 17 | 0.110 |
Why?
|
| Thymus Gland | 1 | 2015 | 10 | 0.110 |
Why?
|
| Chicago | 1 | 2016 | 453 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 281 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 15 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 103 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 9 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2018 | 827 | 0.110 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 1 | 0.100 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 5 | 0.100 |
Why?
|
| Length of Stay | 2 | 2015 | 126 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2011 | 28 | 0.100 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2012 | 1 | 0.090 |
Why?
|
| Dyspnea | 1 | 2012 | 22 | 0.090 |
Why?
|
| Histone Acetyltransferases | 2 | 2009 | 3 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2009 | 157 | 0.090 |
Why?
|
| Fistula | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 3 | 0.090 |
Why?
|
| Esophagectomy | 1 | 2011 | 14 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2011 | 5 | 0.080 |
Why?
|
| Living Donors | 1 | 2011 | 6 | 0.080 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 11 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 30 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 22 | 0.080 |
Why?
|
| Endoleak | 1 | 2010 | 1 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 3 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 8 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 15 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2010 | 21 | 0.080 |
Why?
|
| Surgical Tape | 1 | 2010 | 1 | 0.080 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 2 | 0.080 |
Why?
|
| Conscious Sedation | 1 | 2010 | 4 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2010 | 9 | 0.080 |
Why?
|
| APACHE | 1 | 2010 | 12 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2010 | 99 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 45 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 72 | 0.070 |
Why?
|
| Activins | 1 | 2009 | 1 | 0.070 |
Why?
|
| Follistatin | 1 | 2009 | 1 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2009 | 99 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 85 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 14 | 0.070 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 3 | 0.070 |
Why?
|
| Debridement | 1 | 2009 | 31 | 0.070 |
Why?
|
| Cattle | 1 | 2009 | 54 | 0.070 |
Why?
|
| Registries | 1 | 2009 | 88 | 0.070 |
Why?
|
| Safety | 1 | 2008 | 14 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 126 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2009 | 90 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 171 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 46 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2008 | 30 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2008 | 29 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2008 | 45 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 95 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 75 | 0.070 |
Why?
|
| Age Factors | 1 | 2009 | 350 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 142 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 207 | 0.060 |
Why?
|
| Animals | 1 | 2009 | 2092 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 863 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 4 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 218 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 12 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 47 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 90 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pneumonia | 1 | 2019 | 33 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 151 | 0.030 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 2 | 0.030 |
Why?
|
| Thymoma | 1 | 2017 | 4 | 0.030 |
Why?
|
| Tonsillar Neoplasms | 1 | 2017 | 3 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 8 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 11 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 24 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 30 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 41 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 5 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 4 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 195 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 15 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 42 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 38 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 125 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 48 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 39 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 78 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 110 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 141 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 107 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 290 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 169 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 324 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 2 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 9 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 10 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 13 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2011 | 5 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 44 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 4 | 0.020 |
Why?
|
| Transducers, Pressure | 1 | 2010 | 2 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 46 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 76 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 366 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 2 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 8 | 0.020 |
Why?
|
| Adipokines | 1 | 2008 | 5 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 9 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 33 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 69 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 68 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 63 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 60 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 152 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 256 | 0.020 |
Why?
|